Chargement en cours...
Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies
PURPOSE: To evaluate the efficacy and safety of a submicron formulation of loteprednol etabonate (LE) gel 0.38% instilled three times daily (TID) compared with vehicle for the treatment of inflammation and pain following cataract surgery with intraocular lens implantation, integrated across two mult...
Enregistré dans:
| Publié dans: | Clin Ophthalmol |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6683659/ https://ncbi.nlm.nih.gov/pubmed/31447544 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OPTH.S210597 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|